HomeCompareSNCAF vs JNJ

SNCAF vs JNJ: Dividend Comparison 2026

SNCAF yields 0.09% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $10.5K in total portfolio value· pulled ahead in Year 5
10 years
SNCAF
SNCAF
● Live price
0.09%
Share price
$63.76
Annual div
$0.06
5Y div CAGR
-0.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.8K
Annual income
$9.03
Full SNCAF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SNCAF vs JNJ

📍 JNJ pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNCAFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNCAF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNCAF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNCAF
Annual income on $10K today (after 15% tax)
$7.70/yr
After 10yr DRIP, annual income (after tax)
$7.68/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,978.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNCAF + JNJ for your $10,000?

SNCAF: 50%JNJ: 50%
100% JNJ50/50100% SNCAF
Portfolio after 10yr
$25.0K
Annual income
$2,349.21/yr
Blended yield
9.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SNCAF
Analyst Ratings
7
Buy
Consensus: Buy
Altman Z
3.4
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNCAF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNCAFJNJ
Forward yield0.09%2.13%
Annual dividend / share$0.06$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-0.1%28%
Portfolio after 10y$19.8K$30.3K
Annual income after 10y$9.03$4,689.40
Total dividends collected$90.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: SNCAF vs JNJ ($10,000, DRIP)

YearSNCAF PortfolioSNCAF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,709$9.05$10,592$272.30+$117.00SNCAF
2$11,468$9.05$11,289$357.73+$179.00SNCAF
3$12,280$9.05$12,123$472.89+$157.00SNCAF
4$13,148$9.05$13,141$629.86+$7.00SNCAF
5← crossover$14,078$9.05$14,408$846.81$330.00JNJ
6$15,072$9.04$16,021$1,151.60$949.00JNJ
7$16,136$9.04$18,122$1,588.22$2.0KJNJ
8$17,275$9.03$20,930$2,228.20$3.7KJNJ
9$18,493$9.03$24,792$3,191.91$6.3KJNJ
10$19,796$9.03$30,274$4,689.40$10.5KJNJ

SNCAF vs JNJ: Complete Analysis 2026

SNCAFStock

SNC-Lavalin Group Inc. operates as an integrated professional services and project management company. It operates through Engineering, Design, and Project Management (EDPM); Nuclear; Infrastructure Services; Resources; Infrastructure EPC (Engineering, Procurement, and Construction) Projects; and Capital segments. The EDPM segment provides consultancy, engineering, design, and project management services for the transportation, civil infrastructure, aerospace, defense and security, and technology sectors. The Nuclear segment supports clients across the nuclear life cycle with the spectrum of services, such as consultancy, field, technology, reactor support and decommissioning, and waste management services, as well as EPC management services. This segment also offers new-build and full refurbishment services for reactors; and spare parts. The Infrastructure Services segment undertakes operations and maintenance projects; and provides EPC services for district cooling plants and power substations. This segment also offers engineering solutions for the hydro, transmission and distribution, renewables, energy storage, and intelligent networks and cybersecurity sectors. The Resources segment provides project development, delivery, and support services primarily to the mining and metallurgy sector, as well as Build-Own-Operate contract services. The Infrastructure EPC Projects segment undertakes construction contracts for the mass transit, heavy rail, roads, bridges, airports, ports and harbors, and water infrastructure sectors. The Capital segment invests in infrastructure concessions, such as bridges and highways, mass transit systems, power facilities, energy infrastructure, water treatment plants, and social infrastructure. It has operations in the Asia Pacific, the United Kingdom, Europe, the Middle East, and the Americas. SNC-Lavalin Group Inc. was founded in 1911 and is headquartered in Montreal, Canada.

Full SNCAF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SNCAF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNCAF vs SCHDSNCAF vs JEPISNCAF vs OSNCAF vs KOSNCAF vs MAINSNCAF vs ABBVSNCAF vs MRKSNCAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.